J&J sales top forecast, helped by hepatitis drug

October 14, 2014 By MassDevice Leave a Comment

Nobel Biocare’s Q2 profits double as it fields buyout interest

August 21, 2014 By Brad Perriello Leave a Comment

ConvaTec said to explore 2015 sale

August 19, 2014 By Brad Perriello Leave a Comment

Medtronic’s Q1 earnings beat The Street on modest sales bump

August 19, 2014 By Brad Perriello Leave a Comment

Diabetes: DexCom’s revenues jump 64% in Q2

August 11, 2014 By Arezu Sarvestani Leave a Comment

Diabetes devices maker DexCom (NSDQ:DXCM) got a lot of love from Wall Street after issuing its latest quarterly report, with DXCM shares gaining 14.5% since last week.

EnteroMedics’ losses widen as it chases FDA approval

August 8, 2014 By Arezu Sarvestani Leave a Comment

Minnesota-based EnteroMedics (NSDQ:ETRM) gained modestly this week after announcing its latest financial report, even though the company missed the mark by a penny.

Strong Q4, $750M buyback give CareFusion a boost

August 8, 2014 By Arezu Sarvestani Leave a Comment

Strong Q2, $750M buyback give CareFusion a boost

CareFusion (NYSE:CFN) posted a stellar 4th-quarter, posting double-digit growth in revenues and earnings and beating Wall Street’s estimates.

Masimo sinks as Q2 misses the mark

August 8, 2014 By Arezu Sarvestani Leave a Comment

California device maker Masimo (NSDQ:MASI) got no Wall Street love this week after announcing results for its most recent quarter.

Baxano: Strong Q2, new patents can’t appease Wall Street

August 8, 2014 By Arezu Sarvestani Leave a Comment

Baxano: Strong Q2, $10M raise, new patents and clinical trial can't appease Wall Street

Baxano Surgical (NSDQ:BAXS) just can’t seem to do right by Wall Street.

Thoratec’s new study, $30M buyback can’t stave off Wall Street exodus after dismal Q2

August 7, 2014 By Arezu Sarvestani Leave a Comment

New study, $30M buyback can't save Thoratec from Wall Street exodus after dismal Q2

Circulatory devices maker Thoratec (NSDQ:THOR) took a major hit yesterday as a bleak 2nd-quarter reports and a lowered outlook on the year sent its stock into a nosedive.

Struggling Alere plans to shed some skin after rough Q2

August 6, 2014 By Arezu Sarvestani Leave a Comment

Struggling Alere plans to ditch some units

Massachusetts-based device maker Alere (NYSE:ALR) said in its quarterly earnings call that it’ll shed some of its business units in order to reorganize in the wake of a missed quarter.